[Retracted] EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P‐gp substrates &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt;. Here, EGFR is linked to breast carcinoma.